Sector News

Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

June 29, 2015
Life sciences
Horizon Pharma isn’t exactly the only specialty pharma company hunting for deals. Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping sprees lately, leaving some analysts wondering just what’s left worth buying in the space. But Horizon is much smaller than its specialty peers–meaning it’s got plenty of opportunities, UBS analysts figure.
 
In a research report seen by Investor’s Business Daily, UBS’ Marc Goodman and Ami Fadia pointed out that Horizon–with a market cap just over $5 billion–is at least $9 billion smaller than other on-the-prowl specialty pharmas, meaning it’s “playing in a different sandbox.”
 
Because of its track record and balance sheet, Horizon “has hit the radar of more potential sellers of assets,” leading the analysts to up both their price target on the company’s stock and their revenue estimates.
 
That’s music to the ears of CEO Timothy Walbert, who has said he’s building up Horizon’s leadership and infrastructure “to support a larger organization,” the UBS analysts wrote. Recently, that’s involved foraying into the orphan-drug business with a pickup of osteoporosis treatment Actimmune–and following that up with May’s $1.1 billion acquisition of orphan drugmaker Hyperion.
 
And while it may have once looked like Horizon would need new offerings to fill in for Vimovo and Duexis–a pair of flagship products Express Scripts and CVS booted off their preferred formulary lists last year–sales of those drugs have held up, IBD notes, meaning pickups can only boost things further. The analysts credit that to the company’s “prescriptions made easy” sales method, one they say is “really the key differentiating piece for Horizon.”
 
By Carly Helfand
 

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend